• About us
• Contact

Advertisement

Organisation › Details

Eli Lilly & Co. Inc. (NYSE: LLY)

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. *

 

	Start	1990-01-01 existent
	Group	Eli Lilly (Group)
	Industry	pharmaceutical
	Region	Indianapolis, IN
	Country	United States (USA)
	Street	Lilly Corporate Center
	City	46285 Indianapolis, IN
	Tel	+1-317-276-2000
		Address record changed: 2020-12-02
Basic data	Employees	H: 10,001 to 50,00 (2022-12-31)
	Currency	USD
	Annual sales	28,541,400,000 (sales, net, consolidated (2022) 2022-12-31)
	Profit	6,244,800,000 (2022-12-31)
	Cash	2,067,000,000 (2022-12-31)
		* Document for »About Section«:
		Record changed: 2025-01-12

Advertisement

More documents for Eli Lilly (Group)

• [1] Innovent Biologics, Inc.. (12/16/24). "Press Release: Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca (pirtobrutinib) in Mainland China". San Francisco, CA, Indianapolis, IN & Suzhou....
• [2] Insitro. (10/9/24). "Press Release: Insitro and Lilly Enter Strategic Agreements to Advance Novel Treatments for Metabolic Diseases". South San Francisco, CA....
• [3] NanoSyrinx Ltd.. (9/10/24). "Press Release: NanoSyrinx Closes £10 Million GBP Financing and Appoints Dr. Edwin Moses as Chairman". Coventry....
• [4] Haya Therapeutics SA. (9/4/24). "Press Release: Haya Therapeutics Announces Collaboration with Lilly to Discover Novel Regulatory Genome Targets for Obesity and Related Metabolic Conditions Using Proprietary RNA Platform". Lausanne & San Diego, CA....
• [5] Qiagen N.V.. (9/4/24). "Press Release: Qiagen and Lilly Collaborate to Support Development of a QIAstat-Dx IVD Panel that Identifies Patients at Risk for Developing Alzheimer’s disease". Venlo....
• [6] Morphic Holding, Inc.. (7/8/24). "Press Release: Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease". Indianapolis, IN & Waltham, MA....
• [7] Kurma Partners. (5/2/24). "Press Release: Kurma Partners Announces the Promotion of Hadrien Bouchez to the Position of Partner". Paris....
• [8] Zephyr AI, Inc.. (3/13/24). "Press Release: Zephyr AI Raises $111 Million in Series A Financing". McLean, VA....
• [9] Prism BioLab Co., Ldt.. (1/24/24). "Press Release: Prism BioLab Raises 1.5 Billion Yen in Series C Fundraising to Advance Technologies and Programs Targeting Protein-protein Interactions". Tokyo....
• [10] Eli Lilly and Company. (12/27/23). "Press Release: Lilly Completes Acquisition of Point Biopharma". Indianapolis, IN....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.